Clinical Trials
17 trialsNCT07092514 2026-03-17
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Washington University School of Medicine
Phase 2 Recruiting
NCT03573960 2026-03-06
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Eisai Inc.
Phase 4 Completed
NCT07419932 2026-02-19
NeoLATC
Fujian Medical University
Recruiting
NCT04171622 2026-02-17
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07010393 2025-06-08
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Fujian Medical University
Phase 4 Not yet recruiting
NCT05620134 2024-10-15
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
Phase 1/2 Active not recruiting
NCT04731740 2024-03-25
Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
Saint Petersburg State University, Russia
Phase 2 Withdrawn
NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT01321554 2023-06-22
SELECT
Eisai Inc.
Phase 3 Completed
NCT02702388 2021-11-24
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Eisai Inc.
Phase 2 Completed
NCT03139747 2021-10-15
UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Thomas Jefferson University
Phase 2 Suspended
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01728623 2020-08-14
A Study of E7080 in Subjects With Advanced Thyroid Cancer
Eisai Inc.
Phase 2 Completed
NCT00784303 2020-04-22
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Eisai Inc.
Phase 2 Completed
NCT02430714 2020-01-09
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Eisai Inc.
Completed
NCT03533361 2018-12-17
Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil
Eisai Inc.
Approved for marketing
NCT02211222 2016-03-16
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Eisai Inc.
Approved for marketing